Podewski, A. F.
Glimm, A. M.
Fischer, I.
Bruyn, G. A. W.
Hanova, P.
Hammer, H. B.
Aga, A. B.
Haavardsholm, E. A.
Ramiro, S.
Burmester, G. R.
Backhaus, M.
Ohrndorf, S.
Funding for this research was provided by:
Novartis
AbbVie
Lilly
Pfizer
UCB
MSD
Galapagos
Sanofi
BMS
Charité - Universitätsmedizin Berlin
Article History
Received: 30 May 2022
Accepted: 18 July 2022
First Online: 5 August 2022
Declarations
:
: The study was approved by the ethical committee of the University of Tuebingen Germany (199/2007BO2).All patients signed an informed consent upon inclusion.
: All patients provided informed consent to publish the data.
: This study was funded by AbbVie Deutschland GmbH & Co. KG. AbbVie supported study logistics. AbbVie had no influence on study design, data, analysis, or interpretation of data. HBH is a paid speaker for Lilly, Novartis and AbbVie and employee of the advisory board for AbbVie. ABA is a paid speaker for AbbVie, Eli Lilly, Novartis, Pfizer, and UCB and consultant of AbbVie, Eli Lilly, Novartis, Pfizer, and UCB. SR is a paid speaker for Eli Lilly, MSD, Novartis, and UCB and consultant of AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB, and Sanofi and receives research support from AbbVie, Galapagos, Novartis, Pfizer, and UCB. MB is a paid speaker for AbbVie, BMS, Galapagos, UCB, and Novartis. AFP, A-MG, IF, GAWB, PH, EAH, GRB, and SO declare that they have no competing interests.